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of the disease is unknown. The main symptoms of UC are 
bloody diarrhea, urgency, and abdominal pain.1,2 UC is 
considered to be caused by multiple factors such as genetic 
susceptibility, environmental factors, immune dysregulation, 
and microbial flora. It is found worldwide but most com-
monly in North America and Europe. Ethnically, it is most 
common among Jews and Caucasians, and less common 
in Asians.2,3 However, recently, its incidence is rapidly in-
creasing in Southern Europe, Asian countries such as South 
Korea, Japan and China, and in developing countries, result-
ing in the increase in the numbers of patients diagnosed as 
having UC.3-6 Various diagnostic methods and treatments 
have been suggested based on scientific evidences obtained 
INTRODUCTION
Ulcerative colitis (UC) is a chronic IBD localized in the 
mucosa and submucosa of the colon. The specific cause 
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through many studies. However, many problems are still 
dealt with physicians’ subjective judgments and experiences. 
Therefore, many countries, including the Unites States and 
Europe, have developed guidelines for UC according to each 
country’s circumstances.
The IBD Study Group of the Korean Association for the 
Study of Intestinal Diseases (KASID) developed the Korean 
guidelines for the diagnosis of UC7 by adapting the Ameri-
can and European guidelines8,9 in 2009. In 2012, the Korean 
guidelines for the management of UC10 was developed and 
published by using the same method of adapting foreign 
guidelines.1,8,11,12 This updated version of the Korean guide-
lines for the management of UC was developed also by 
adapting foreign guidelines that were reported within the 
recent 5 years.13-21
These guidelines are not suggesting absolute standards 
but is aimed at helping physicians make the best decisions 
for managing patients with UC according to scientific evi-
dences available. Therefore, physicians may make final deci-
sions by considering each patient’s specific situations. These 
guidelines should neither limit the physician’s medical 
practice nor be used to set the standards for Korean medical 
insurance. Moreover, this does not indicate legal criteria for 
medical practice conducted on specific patients.
We are hoping that these guidelines will prevent unneces-
sary or inappropriate or delayed treatments and lessen the 
confusion among physicians and researchers by making use 
of the same terms related to UC.
METHODS
1. Direction
The IBD Study Group of the KASID decided to produce 
an updated version of the Korean guidelines for the man-
agement of UC in July 2015. To establish the guidelines, a 
subcommittee was formed, consisting of eight gastroenterol-
ogists who were members of the KASID, one colorectal sur-
geon who was a member of the Korean Society of Coloproc-
tology, and one professor of preventive medicine who was a 
methodologist for guidelines development. All members of 
the subcommittee attended 10 meetings until the comple-
tion of the guidelines starting from July 12, 2015.
This updated guidelines included treatment of active coli-
tis, maintenance of remission, and indication of surgery for 
UC in adults. Managements of specific situations such as ex-
traintestinal manifestations, pouchitis, pediatric or pregnant 
patients, and colitic cancer surveillance are not included in 
these guidelines. These guidelines were generally made by 
the adaptation of foreign guidelines for the management of 
UC, as was the first Korean guideline. The recommendations 
for three key questions not precisely included in other guide-
lines were newly made by using the Grading of Recommen-
dation Assessment, Development and Evaluation (GRADE) 
format.
2. Process of Development
1) Selection of the Key Questions
The key questions were selected from among those raised 
in actual clinical practice through subcommittee meetings 
and discussions. Three of the key questions were decided to 
be solved by de novo development; and the remaining ques-
tions, by adaptations.
2) Searching for Source Guidelines
Twenty-seven articles with publication dates between 
January 2011 and June 2015 were selected by searching the 
MEDLINE/PubMed and National Guidelines Clearinghouse 
web sites.
3) Assessment of Guideline Qualities and Final Selection
First, we selected 16 English guidelines based on whether 
they were evidence based, peer reviewed, and national or in-
ternational guidelines. Each foreign guideline was evaluated 
by two subcommittee members on its academic integrity 
and applicability to actual clinical practice according to the 
Appraisal of Guidelines Research and Evaluation II. Finally, 
nine highly qualified guidelines were selected and then 
analyzed and summarized for their evidences and medical 
recommendations for our guidelines (Table 1).13-21
4) Adaptation
The evidences and recommendations of the nine selected 
guidelines were reviewed, analyzed, and summarized for the 
development of our recommendations and backgrounds. 
Recent studies that were reported after the search period 
for referential guidelines were included additionally as evi-
dences for our guidelines. Some of the information was con-
sidered not sufficiently evidenced and thus was discussed in 
the IBD specialist meetings to be included in the guidelines.
The quality of the evidence and classification of the rec-
ommendation in these guidelines are presented according 
to the GRADE format.22-24 Following the GRADE format, we 
assessed the quality of evidence for each recommendation 
as high, moderate, low, and very low. The strength of each 
recommendation was evaluated based on four main com-
ponents, which are desirable and undesirable effects, quality 
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of the evidence, values and preference, and lastly, resource 
allocation, and classified as strong or weak.24,25 The definition 
of quality of evidence and classification of the recommenda-
tions are shown in Table 2.22-25
5) De novo Development
De novo development was conducted for three key ques-
tions by following the GRADE format as follows: efficacy of 
cyclosporine and tacrolimus for corticosteroid-refractory 
Table 1. Nine Guidelines Selected for Adaptation
No. Title Country Journal Year Volume/page
1 Ulcerative colitis: management in adults, children and young people13 United Kingdom National Clinical 
Guideline Centre
2013 -
2 Treatment of hospitalized adult patients with severe ulcerative colitis: 
Toronto consensus statements14
Canada American Journal of 
Gastroenterology
2012 107/179-194
3 Clinical practice guidelines for the medical management of 
nonhospitalized ulcerative colitis: the Toronto consensus15
Canada Gastroenterology 2015  148/1035-1058
4 The London position statement of the World Congress of 
Gastroenterology on Biological Therapy for IBD with the European 
Crohn’s and Colitis Organization: when to start, when to stop, which 
drug to choose, and how to predict response?16
World Congress of 
Gastroenterology
American Journal of 
Gastroenterology
2011 106/199-212
5 The London position statement of the World Congress of 
Gastroenterology on Biological Therapy for IBD with the European 
Crohn’s and Colitis Organization: safety21
World Congress of 
Gastroenterology
American Journal of 
Gastroenterology
2011  106/1594-1602
6 Second European evidence-based consensus on the diagnosis and 
management of ulcerative colitis part 2: current management17
European Union Journal of Crohn’s 
and Colitis
2012 6/991-1030
7 Therapeutic guidelines on ulcerative colitis: a GRADE methodology 
based effort of GETECCU18
Spain Gastroenterología y 
Hepatología
2013 36/104-114
8 Guidelines for the management of inflammatory bowel disease in 
adults19
United Kingdom Gut 2011 60/571-607
9 The Italian Society of Gastroenterology (SIGE) and the Italian Group for 
the Study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice 
Guidelines: the use of tumor necrosis factor-α antagonist therapy in 
inflammatory bowel disease20
Italy Digestive and Liver 
Disease 
2011 43/1-20
GRADE, Grading of Recommendation Assessment, Development and Evaluation; GETECCU, Grupo Español de Trabajo Enfermedad de Crohn y Colitis 
Ulcerosa.
Table 2. Definitions or Implications of the Levels of Evidence and Recommendations22-25
Level Definition/implication
Quality of evidence
  High We are very confident that the true effect lies close to that of the estimate of the effect.
  Moderate We are moderately confident about the effect estimate: the true effect is most likely to be close to the 
estimate of the effect, but there is a possibility that it is substantially different.
  Low Our confidence in the effect estimate is limited: the true effect may be substantially different from the 
estimate of the effect.
  Very low We have very little confidence in the effect estimate: the true effect is most likely to be substantially 
different from the estimate of the effect.
Classification of recommendations
  Strong Most patients should receive the recommended course of action.
  Weak Clinicians should recognize that different choices would be appropriate for different patients and 
that they must help patients to arrive at a management decision consistent with their values and 
preferences.
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severe UC and efficacy of high-dose 5-aminosalicylic acid 
(5-ASA) for maintenance of remission. The PubMed and 
EMBASE databases were used for searching evidences about 
the key questions. Language was limited to Korean and Eng-
lish. The study design included randomized controlled trials 
(RCTs) and prospective and retrospective cohort studies. 
Editorials, letters, and proceedings were excluded.
6) Delphi Process for the Agreement to Recommendations
On September 25, 2016, the draft of the updated Korean 
guidelines for the management of UC was presented during 
the consensus meeting attended by 53 national IBD special-
ists. Each recommendation in the guideline was evaluated 
into five levels, namely strongly agree, agree, uncertain, dis-
agree, and strongly disagree. Each recommendation in the 
guidelines were selected when more than 75% of the par-
ticipants have answered strongly agree or agree. When the 
percentage of agreement on the guidelines were below 75%, 
the guidelines subcommittee went through a discussion and 
modification, and proceeded with secondary online voting. 
The secondary online voting for the guidelines proceeded 
by 49 of the 53 IBD specialists who participated in the pri-
mary evaluation. The final result was indicated as a percent-
age under the classification of recommendation, as “level of 
agreement.”
7) Review, Endorsement, and Distribution of Guidelines
The revised draft was reviewed and approved by the mem-
bers of the KASID. The final draft was co-published by the 
Korean Journal of Gastroenterology and Intestinal Research 
for facilitated distribution and will be distributed by the Ko-
rean Medical Guideline Information Center (http://www.
guideline.or.kr). The second updated version is planned to 
be published, including opinions by users and newly pre-
sented information on the management of UC.
THERAPEUTIC APPROACH
The goal of the management of UC is to improve patients’ 
quality of life by relieving mucosal inflammation and main-
taining remission as long as possible. Among UC patients, 
15% are known to achieve the remission state even with only 
placebo treatment.26 However, starting and maintaining the 
appropriate treatments to relieve symptoms such as bloody 
stool and diarrhea are reasonable. These guidelines are di-
vided into three sections as follows: medical management of 
active UC, maintenance of remission, and surgical therapy.
The important keys in decision making on the treatment 
of UC are the extent, severity, and clinical features of the 
disease. Medications differ in distribution area within the 
bowel, and topical agents can be locally effective. In addition, 
the potency and adverse effects of the medication, response 
to the previous treatment, and extraintestinal manifestations 
must be considered.
Extent of the disease was classified into proctitis (up to 15 
cm above the anal verge), left-sided colitis (up to the splenic 
flexure), and extensive colitis (beyond the splenic flexure) 
according to the diagnostic guideline for UC.7 Clinical sever-
ity was classified in accordance with the modification of the 
Truelove and Witts score.27 It is divided into remission, mild, 
moderate, and severe groups (Table 3).12
5-ASA are described in the main text as treatment agents 
for UC. There are different types of 5-ASA according to the 
mediator used to deliver them to the small and large in-
testines. Sulfasalazine, a combination of sulfapyridine and 
5-ASA by azo bond, has been used for a long time. The newly 
developed 5-ASA are olsalazine (5-ASA dimer), balsalazide 
(Colazal®, 5-ASA combined with 4-amino-benzoyl-β-alanine 
by azo bond), Eudragit-S-coated mesalamine (Asacol®), 
Eudragit-L-coated mesalamine (Salofalk®), ethylcelllulose-
coated microgranules of mesalamine (Pentasa®), and MMX 
mesalamine (Mezavant®), which is made by using the multi-
matrix system (MMX) (Table 4).
The new 5-ASA preparations have almost similar effects as 
sulfasalazine but are safer. The adverse effects of sulfasala-
zine are usually due to its sulfapyridine component, which 
Table 3. Truelove and Witts Score for Clinical Severity of UC12,27
Milda Moderate Severeb
(1) Frequency of 
defection
4 Times or less Intermediate 
between mild 
and severe
6 Times or more
(2) Bloody stool (−) or (+) (+++)
(3) Feverc Absent 37.5oC or higher
(4) Tachycardiad Absent 90/min or more
(5) Anemia Absent Hb 10 g/dL or less
(6) ESR Normal 30 mm/h or more
aRated as “mild” when all 6 criteria are satisfied.
bRated as “severe” when criteria (1) and (2), and either of systemic 
symptoms (3) and (4) are satisfied, and at least 4 of the 6 criteria are 
satisfied.
cMean evening temperature of >37.5oC or a temperature of ≥37.8oC at 
least 2 of 4 days.
dMean pulse rate of >90/min.
Hb, hemoglobin.
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causes nausea, vomiting, indigestion, headache, pancreatitis, 
hepatitis, drug-induced connective tissue disorders, marrow 
suppression, interstitial nephritis, hemolytic anemia, mega-
loblastic anemia, and reversible male infertility.1,28-30 In 80% 
of patients with adverse effects of sulfasalazine use, other 
5-ASA provide relief. All 5-ASA except sulfasalazine are rec-
ommended to patients with pregnancy plans.
In rare cases, 5-ASA, including sulfasalazine, can lead to 
nephrotoxicity (yearly prevalence of 0.26%/person/year). 
Usually interstitial nephrotoxicity develops in the first year of 
treatment. It is considered idiosyncratic, as 5-ASA dosage is 
not associated with nephrotoxicity. Therefore, even though it 
is not absolutely required, evaluation of serum creatinine level 
is needed before and after the use of 5-ASA. For the first year, 
3 to 6 months of follow-up for evaluation of creatinine level is 
recommended. After 1 year, yearly evaluation is needed.1,31
MEDICAL MANAGEMENT OF ACTIVE UC
1. Management of Mild to Moderate UC
1) Proctitis
1. The preferred initial treatment of mild to moderate 
proctitis is administration 5-ASA suppository 1 g/day or 
enema 1–2 g/day (quality of evidence, high; classifica-
tion of recommendation, strong).
• Level of agreement: strongly agree 53.3%, agree 43.3%, 
uncertain 3.3%, disagree 0%, strongly disagree 0%
2. Topical corticosteroids are recommended when topical 
5-ASA are ineffective or have adverse effects (quality 
of evidence, very low; classification of recommendation, 
weak).
• Level of agreement: strongly agree 11.4%, agree 84.1%, 
uncertain 4.6%, disagree 0%, strongly disagree 0%
3. Using topical 5-ASA in combination with oral 5-ASA 
(≥2.0 g/day) or topical corticosteroid is more effective 
than using it individually and should be considered for 
escalation of treatment (quality of evidence, high; clas-
sification of recommendation, strong).
• Level of agreement: strongly agree 60.5%, agree 37.2%, 
uncertain 2.3%, disagree 0%, strongly disagree 0%
4. Evaluation of treatment response is recommended after 
4–8 weeks of oral/rectal 5-ASA induction therapy to de-
termine the need to modify therapy (quality of evidence, 
very low; classification of recommendation, strong).
• Level of agreement: strongly agree 15.9%, agree 72.7%, 
uncertain 11.4%, disagree 0%, strongly disagree 0%
5. Oral corticosteroids (prednisolone 30–40 mg/day, or 
0.5–1.0 mg/kg) are recommended when 5-ASA and/or 
topical corticosteroid therapies are ineffective (qual-
ity of evidence, low; classification of recommendation, 
strong).
• Level of agreement: strongly agree 36.4%, agree 56.8%, 
uncertain 4.6%, disagree 2.3%, strongly disagree 0%
If the extent of the disease is limited to the rectum, topical 
5-ASA are recommended for initial treatment. Topical 5-ASA 
have been effective for remission induction in mild to mod-
erate proctitis in several meta-analyses.32-37 In a meta-anal-
ysis of 11 studies with 778 patients with proctitis or distal 
Table 4. Delivery System for 5-ASA9
5-ASA Delivery system
Azo bond
   Sulfasalazine (500 mg/tablet) Sulfapyridine carrier
   Olsalazine (250 mg/capsule) 5-ASA dimer
   Balsalazide (750 mg/capsule) 4-Amino-benzoyl-β-alanine
Controlled release
   Pentasa® (500 mg or 1,000 mg/tablet) Ethylcellulose-coated microgranules
pH 7-dependent
   Asacol® (400 mg/tablet) Eudragit-S coating, dissolves at pH 7
pH 6-dependent
   Salofalk® (250 mg/tablet) Eudragit-L coating, dissolves at pH 6
Composite (multi-matrix, 1,200 mg/tablet)
   Mezavant® (European Union)
   Lialda® (United States) 
Eudragit-S coating of hydrophilic polymer with  
some 5-ASA and lipophilic excipients encapsulating 5-ASA
5-ASA, 5-aminosalicylic acid.
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colitis, placebo treatment showed a remission rate of 7% to 
11%, while topical 5-ASA treatment showed a remission rate 
of 31% to 80% (median, 67%).38 In a Cochrane meta-analysis 
that examined 38 clinical trials for proctitis and left-sided 
colitis, the effect of topical 5-ASA on remission induction was 
better than that of placebo (OR, 8.30; 95% CI, 4.28−16.12), 
endoscopic findings (OR, 5.31; 95% CI, 3.15−8.92), and his-
tologic findings (OR, 6.28; 95% CI, 2.74−14.40).37 In a recent 
randomized controlled study for ulcerative proctitis, the 
remission rate after 4 weeks was 83.8% in the topical 5-ASA 
(suppository) group, which was higher than the 36.1% in the 
placebo group.39
The percentage of residual drug 4 hours after rectal ad-
ministration was 40% for the foam type but only 10% for the 
liquid type.40 Therefore, suppositories may be more effective 
in delivering the drug directly to the inflammatory lesion of 
proctitis. A topical 5-ASA dose of 0.25 to 1 g/day is effective, 
and a dose higher than 1 g/day has no dose response.41 No 
difference in effect was found between using 5-ASA supposi-
tory once a day and dividing the same dosage to twice or 
three times a day.42,43
In a meta-analysis, topical corticosteroids presented better 
outcomes than placebo in terms of remission induction.44 
However, topical 5-ASA showed better effects on symptom 
relief (OR, 2.42; 95% CI, 1.72−3.41), endoscopic findings (OR, 
1.89; 95% CI, 1.29−2.76), and histological finings (OR, 2.03; 
95% CI, 1.28−3.20) than topical corticosteroids.44 A meta-anal-
ysis of six clinical trials showed that topical 5-ASA had better 
outcomes than topical corticosteroids in terms of symptom 
remission (OR, 1.65; 95% CI, 1.11−2.45).37 5-ASA also showed 
better effects on remission induction compared with topical 
budesonide.44-46 Therefore, topical corticosteroids should be 
used in patients who fail to respond to topical 5-ASA or who 
experience adverse effects of topical 5-ASA use.47
Previous studies reported that topical 5-ASA show better 
effects than the oral 5-ASA in proctitis.48 However, a meta-
analysis of four clinical trials showed that topical 5-ASA did 
not have better outcomes than oral 5-ASA in terms of symp-
tom relief (OR, 2.25; 95% CI, 0.53−9.54; P=0.27) or remission 
induction (RR, 0.82; 95% CI, 0.52−1.28).34,37 In using oral 
5-ASA alone, 3.6 g/day showed better outcomes than low-
dose 5-ASA or placebo. Therefore, high-dose administration 
may be better when oral 5-ASA monotherapy is used in 
proctitis.49 No study has evaluated the effect of combination 
therapy with oral and topical 5-ASA on proctitis. However, 
combination therapy has been demonstrated to be better 
than monotherapy in the treatment of left-sided colitis lo-
cated within 50 cm above the anal verge.50 In addition, com-
bination therapy with a topical 5-ASA and a topical cortico-
steroid will be more effective than using them individually. 
Combined treatment with beclomethasone dipropionate 
(BDP; 3 mg) and 5-ASA enema (2 g) has shown better clini-
cal, endoscopic, and histological outcomes than using them 
separately as monotherapy.51
In a randomized controlled study on 5-ASA treatments, 
symptomatic remission was induced in 10% to 30% of pa-
tients after 2 weeks of treatment, 30% to 45% of patients 
after 4 weeks, and 45% to 50% of patients after 8 weeks.52,53 
The median period to symptomatic remission was 10 to 37 
days.52,53 Generally, the response to 5-ASA appeared within 
2 to 4 weeks of treatment, and additional effect may con-
tinue until 16 weeks.45,46,50,53-56 If symptoms are not improved 
within 4 to 8 weeks of 5-ASA treatment, other therapies can 
be considered. If adequate administration of topical and/
or oral 5-ASA and topical corticosteroids does not alleviate 
symptoms or if systemic symptoms are observed during the 
treatment, oral corticosteroids can be used. If oral corticoste-
roid treatment does not improve the symptoms, biological 
therapy can be considered.17
2) Left-Sided and Extensive Colitis
6. Oral 5-ASA at a dosage of ≥2.4 g/day is recommended 
for mild to moderate left colitis and extensive colitis 
(quality of evidence, moderate; classification of recom-
mendation, strong).
• Level of agreement: strongly agree 74.5%, agree 23.4%, 
uncertain 2.1%, disagree 0%, strongly disagree 0%
7. Combination therapy with oral 5-ASA and topical 5-ASA 
(0.25–1.0 g/day) is more effective than monotherapy 
with oral 5-ASA (quality of evidence, low; classification 
of recommendation, strong).
• Level of agreement: strongly agree 48.9%, agree 44.7%, 
uncertain 4.3%, disagree 2.1%, strongly disagree 0%
8. Remission induction effect is similar between taking 
oral 5-ASA once a day and taking the same dosage di-
vided times a day. Therefore, decision should be made 
based on patient’s preference and compliance (quality 
of evidence, moderate; classification of recommenda-
tion, strong).
• Level of agreement: strongly agree 44.9%, agree 55.1%, 
uncertain 0%, disagree 4.6%, strongly disagree 0%
9. Oral corticosteroid (prednisolone 30–40 mg/day, or 
0.5–1.0 mg/kg) is recommended when adequate use of 
5-ASA is ineffective or accompanied by systemic symp-
toms (quality of evidence, low; classification of recom-
mendation, strong).
• Level of agreement: strongly agree 48.9%, agree 51.1%, 
uncertain 0%, disagree 0%, strongly disagree 0%
https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37
13www.irjournal.org
Oral 5-ASA are recommended for remission induction in 
patients with mild to moderate left-sided and extensive coli-
tis.32,57 A meta-analysis about the effect of oral 5-ASA in mild 
to moderate UC showed that the remission failure rate in the 
oral 5-ASA group (0.86; 95% CI, 0.81−0.91) was lower than 
that in the placebo group (0.79; 95% CI, 0.73−0.85), indicat-
ing the therapeutic effects of oral 5-ASA treatment in mild to 
moderate UC.32,58,59 Another meta-analysis reported that oral 
5-ASA treatment was twice more effective than placebo60 
and that the remission induction rate of 5-ASA was about 
20% to 40%.61 In meta-analyses, oral 5-ASA treatment was 
more effective when it was administrated at ≥2.0 g/day.58,59 In 
addition, in the ASCEND II study (Assessing the Safety and 
Clinical Efﬁcacy of a New Dose of 5-ASA), the median time 
to rectal bleeding cessation was 9 days with 4.8 g/day of oral 
5-ASA, which was significantly lower than the median time 
of 16 days of oral 5-ASA at 2.4 g/day (P <0.05).62 Therefore, 
administration of 2.4 g/day of oral 5-ASA may be adequate 
for mild UC. However, considering that high-dose oral 5-ASA 
does not result in any adverse effect, a higher dose of oral 
5-ASA is recommended for patients with moderate UC. In 
a randomized case-control study, 10% to 30% of patients 
showed symptom remission in the second week of 5-ASA 
treatment; 30% to 45%, in the fourth week; and 45% to 50%, 
in the eighth week. Most of the patients showed response to 
the 5-ASA treatment within 2 to 4 weeks of treatment and 
additional effect continued until 16 weeks.45,46,50,53-56
For mild to moderate left-sided and extensive colitis, com-
bination therapy with oral and topical 5-ASA treatment is 
recommended. Topical therapy can elevate the 5-ASA level 
in the rectal mucosa more than oral therapy, which can 
result in clinical improvement.63 A meta-analysis of four ran-
domized placebo-controlled studies revealed that combined 
treatment with oral and topical 5-ASA is more effective than 
oral 5-ASA monotherapy (remission failure rate, 0.65; 95% 
CI, 0.47−0.91).34 In addition, the remission induction rate 
with combination therapy with oral 5-ASA (Pentasa®) at 4 g/
day and rectal enema at 1 g/day in 8 weeks is 64%, which is 
significantly higher than the remission induction rate of 43% 
with oral 5-ASA monotherapy.64
In the past, sulfasalazine was the primary choice for oral 
5-ASA medication. Recently, mesalamine has been most 
commonly used. Other 5-ASA such as olsalazine and balsala-
zide, are also used and have better therapeutic effects than 
placebo for active UC.60 The choice of oral 5-ASA agents is 
based on consideration of tolerance, prescription, and price. 
Meta-analyses revealed no difference in effect or safety be-
tween the types of 5-ASA.58,65 Therefore, changing oral 5-ASA 
to different types of 5-ASA because of lack of response is not 
recommended. Choosing a different method of treatment 
will be a better option.
As the effect of oral 5-ASA can differ according to its dosage 
rather than delivery method, patients’ compliance is an im-
portant factor. Recent studies showed that taking oral 5-ASA 
once a day presented similar or even better results than 
dividing the same dosage twice or three times a day.66,67 A 
meta-analysis of 11 studies showed that remission rate (RR, 
0.95; 95% CI, 0.82−1.10) and response rate (RR, 0.87; 95% CI, 
0.68−1.10) had no significant difference between the patients 
with mild to moderate UC who took oral 5-ASA once a day 
or three times a day.66 In addition, most patients preferred 
once a day administration to dividing the dose.67,68 Therefore, 
in mild to moderate UC, administration of oral 5-ASA once 
a day is recommended for remission induction in consid-
eration of patients’ compliance. However, dividing the dose 
could be chosen according to the patient’s preference.
MMX mesalamine is a medication that was newly devel-
oped by using the MMX technique and widely distribute the 
high concentration of 5-ASA (1.2 g/tablet) throughout the 
whole colon mucosa when taken once a day. In patients with 
mild to moderate UC, remission rate after 8 weeks in the 
MMX mesalamine 4.8 g once daily group and 2.4 g twice dai-
ly group showed no significant difference (29% vs. 34%) but 
was significantly different from that with placebo (13%).69 
In a comparison study between MMX mesalamine and 
Asacol®, the clinical remission rate in mild to moderate UC 
was 40.5% in patients who received MMX mesalamine 2.4 g/
day and 41.2% in patients who received MMX mesalamine 
4.8 g/day. These results showed significant differences in 
remission rate when compared with that in placebo (22.1%; 
P=0.010 and P=0.007, respectively) but no significant differ-
ence with Asacol® (2.4 g/day, 32.6%).70
For patients with mild to moderate UC, oral corticosteroid 
treatment could be decided according to the effect of 5-ASA 
and patients’ tolerance and preference for treatments. The ef-
fect of corticosteroid therapy on UC has been reported since 
the 1960s. Physicians should discuss with their patients the 
effect and possible adverse effects of using corticosteroids. 
If adequate 5-ASA therapy (≥2.4 g/day) combined with topi-
cal treatment does not improve the patient’s symptom or 
if the symptom remains even after 4 weeks of proper treat-
ment, additional oral corticosteroid therapy is needed.17 Oral 
corticosteroid can also be used for patients with worsening 
symptoms during azathioprine (AZA) maintenance therapy. 
Europe and the United States have differing opinions about 
when to start the corticosteroid treatment. In Europe, corti-
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costeroids are used early because of late response to 5-ASA, 
whereas in the United States, their use is delayed because of 
the potential adverse effects.
No definite guidelines have been established yet for opti-
mal corticosteroid use for UC. However, according to a meta-
analysis, corticosteroids administered at a dosage of ≥60 mg/
day have no additional effect. Therefore, oral corticosteroids 
(prednisolone) 30 to 40 mg/day are recommended for re-
mission induction.71 Usually, a dosage of 30 to 40 mg/day is 
recommended until clinical improvement is observed and 
is tapered to 5 to 10 mg per week up to 20 mg. Thereafter, 
lowering the dosage to 2.5 mg per week is recommended.72,73 
The Japanese UC management guidelines recommend 
prednisolone 30 to 40 mg/day.12 There are at high risk of 
early recurrence in active UC when using corticosteroids in 
less than 3 weeks. Prednisolone <15 mg/day is ineffective for 
primary treatment.74 Corticosteroid is highly effective for re-
mission induction; however, 50% of patients can experience 
adverse effects such as acne, emotional change, or edema.17
BDP has few systemic adverse effects due to its low bio-
availability. It is also effective for remission induction of mild 
to moderate UC.75 Among patients with mild to moderate 
UC that was unresponsive to oral 5-ASA, when oral BDP 10 
mg/day was used for 8 weeks and followed 5 mg/day for 4 
weeks, 75% showed clinical remission at 8 weeks and 58% 
remained in remission state for 1 year without using corti-
costeroid therapy.76 In addition, in a meta-analysis of seven 
randomized placebo-controlled studies that compared re-
mission induction and clinical improvement between 5-ASA 
and BDP for mild to moderate UC, no significant difference 
(OR, 0.76; 95% CI, 0.56−1.03; P=0.08) was found, as well as ad-
verse effects.77 Budesonide MMX is a newly developed topi-
cal corticosteroid that was reported in the Colonic Release 
Budesonide I and II studies to show effectiveness in mild to 
moderate UC patients who were intolerant or nonresponsive 
to 5-ASA.78,79 Therefore, using topical corticosteroids should 
be considered before using systemic corticosteroids.
3) Corticosteroid-Refractory Mild to Moderate UC
10. Anti-tumor necrosis factor (TNF) therapy is recommend-
ed when adequate dosage and duration of treatment 
with corticosteroid or combination of corticosteroid and 
thiopurine do not improve symptoms, or if the treat-
ment is not tolerable to the patient (quality of evidence, 
high; classification of recommendation, strong).
• Level of agreement: strongly agree 55.6%, agree 44.4%, 
uncertain 0%, disagree 0%, strongly disagree 0%
The possibility of cytomegalovirus (CMV) reactivation or 
Clostridium difficile  infection must be considered in active 
UC patients who are unresponsive to corticosteroid treat-
ment.
Studies on thiopurine therapy (6-mercaptopurine [6-MP] 
or AZA) for remission induction in active UC are rare.80,81 In 
one randomized case-control study, the effect of combination 
therapy with corticosteroid and AZA (2 mg/kg/day) on clini-
cal and endoscopic remission induction was better than that 
of monotherapy with oral 5-ASA in patients with corticoste-
roid-dependent UC (intent-to-treat analysis, 53% vs. 21%; OR, 
4.78; 95% CI, 1.57−14.50).80 However, for patients with active 
UC, thiopurine monotherapy is not recommended because 
it requires at least 2 to 3 month to take effect.82,83 Thiopurine 
therapy is mostly used to lower the corticosteroid dosage in 
corticosteroid-dependent patients rather than to induce re-
mission.80,84-89
Anti-TNF therapy is recommended to patients with mod-
erate UC when adequate dosage and duration of treatment 
with corticosteroid or combination of corticosteroid and thio-
purine do not improve symptoms or are not tolerated by the 
patient. Still, studies about the effect of anti-TNF therapy on 
mild UC are rare. In South Korea, infliximab, adalimumab, and 
golimumab are used as anti-TNF therapy, all of which showed 
therapeutic effects in terms of remission induction and main-
tenance in patients with moderate to severe active UC.
The effect of infliximab was clearly proved through two 
large-scale RCTs, namely Active UC Trials 1 (ACT-1) and 
2 (ACT-2).90 The ACT study analyzed the clinical response 
and remission rates of 728 patients with moderate to severe 
UC by dividing them into three groups as follows: the inflix-
imab 5 mg/kg, infliximab 10 mg/kg, and placebo groups. The 
ACT-1 study was conducted with patients who showed no 
response to corticosteroid or thiopurine treatment. The re-
sults of the ACT-1 study showed significantly higher clinical 
response rate to infliximab treatment than to placebo in the 
8th, 30th, and 54th weeks (5 mg/kg, 10 mg/kg, and placebo, 
respectively; 45%, 44%, and 20%, respectively; P<0.001), and 
a post hoc analysis also showed lower colectomy rate in the 
infliximab-treated group than in the placebo group.91
Adalimumab is also effective in patients with moderate to 
severe UC regarding remission induction. Among patients 
with moderate to severe UC treated with corticosteroid or 
immunomodulators, the adalimumab 160/80 mg (18.5%) 
group showed a higher remission rate than the placebo 
group (9.2%) at 8 weeks of treatment in UC long-term re-
mission and maintenance with adalimumab 1 (ULTRA 1) 
study.92 In addition, in the ULTRA 2 study, remission rate at 
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8 weeks was higher in the 160/80 mg adalimumab group 
(16.5%) than in the placebo group (9.3%) (P=0.019)and that 
at the 52 weeks of treatment was also significantly higher in 
the adalimumab group (17.3%) than in the placebo group 
(8.5%) (P=0.004).93 In a subanalysis of patients with moder-
ate to severe UC who previously used infliximab and were 
currently using corticosteroids or immunomodulators, the 
remission rate at the 52 weeks without corticosteroid use 
was significantly higher in the adalimumab group (10.2%) 
than in the placebo group (3.0%).93 Therefore, it is proved in 
the ULTRA 1 and ULTRA 2 studies that adalimumab is more 
effective for remission induction than placebo in patients 
with moderate to severe UC who showed lack of response 
to corticosteroids or immunomodulators (remission failure 
OR, 0.60; 95% CI, 0.42−0.86).92,93
The effect of golimumab was confirmed in the Program of 
UC Research Studies Utilizing an Investigational Treatment-
Subcutaneous (PURSUIT-SC), which presented a significant 
difference in remission rate at the 6 weeks of treatment, 
51.0% in the golimumab 200 mg/100 mg group and 30.3% in 
the placebo group (P<0.001).94
In recent UC SUCCESS study, patients with moderate to 
severe UC who never used anti-TNF therapy showed a sig-
nificant difference in remission rate without corticosteroids 
at 16 weeks. The remission rate of the group who received 
combination therapy with infliximab and AZA was 39.7%, 
which was higher than those of the groups who received 
infliximab monotherapy (22.1%) and AZA monotherapy 
(23.7%).95 This study proved that thiopurine therapy increas-
es the remission rate in UC as well as CD by suppression of 
immunogenicity, which lowers the production of the anti-
infliximab-antibody.
2. Management of Moderate to Severe UC
1) Conventional and Corticosteroid Therapies
11. Oral corticosteroid administration is recommended as 
initial remission induction treatment of moderate to se-
vere UC (quality of evidence, moderate; classification of 
recommendation, strong).
• Level of agreement: strongly agree 52.2%, agree 45.7%, 
uncertain 2.2%, disagree 0%, strongly disagree 0%
12. Patients with severe UC who have systemic toxic symp-
toms need to be admitted and treated with intravenous 
corticosteroids (methylprednisolone 40−60 mg/day or 
hydrocortisone 300−400 mg/day) (quality of evidence, 
high; classification of recommendation, strong).
• Level of agreement: strongly agree 85.1%, agree 14.9%, 
uncertain 0%, disagree 0%, strongly disagree 0%
13. To confirm the response of patients with severe UC to 
intravenous corticosteroid treatment, frequency of bow-
el movement, CRP level, and simple abdominal radiogra-
phy must be assessed within 3−7 days after treatment. 
If no improvement is observed after 7−14 days, further 
treatment methods, including intravenous cyclosporine 
therapy, anti-TNF therapy, and surgery must be dis-
cussed (quality of evidence, moderate; classification of 
recommendation, strong).
• Level of agreement: strongly agree 53.2%, agree 44.7%, 
uncertain 0%, disagree 2.1%, strongly disagree 0%
According to a meta-analysis of five randomized placebo-
controlled studies, remission induction with corticosteroid 
was excellent compared with placebo treatment, and the rel-
ative risk of remission failure was 0.65 (95% CI, 0.45−0.93).96 
Although the adequate corticosteroid dosage is not yet 
known, 40 to 60 mg/day oral prednisolone is mostly recom-
mended because no additional response was found in dos-
ages of >60 mg/day in the meta-analysis.71 However, half of 
the patients experience short-term adverse effects such as 
acne, edema, sleep disorder, mood disorder, glucose intoler-
ance, and indigestion.97,98
Acute severe UC with systemic symptoms is considered a 
medical emergency, and the patient must be admitted and 
treated with intravenous corticosteroids. Administration of 
intravenous corticosteroids has been demonstrated to signif-
icantly lower the mortality rate in such patients.71,99 Various 
intravenous corticosteroid therapies are available. However, 
the types of medication or method of injection (bolus vs. 
continuous) does not lead to a difference in effect.100 Cur-
rently, intravenous methylprednisolone 40 to 60 mg/day or 
its equivalent is recommended.71
Few studies have been conducted on the effect of topi-
cal and intravenous corticosteroid combination therapy. 
However, if the patient is compliant, suppository therapy or 
corticosteroid or 5-ASA enema therapy can be used.101 More-
over, when the patient is capable of taking oral medication, 
5-ASA can be used together with intravenous corticosteroid 
therapy. Adequate fluid supply is important to correct dehy-
dration and electrolyte imbalance. Potassium supplement 
(≥60 mmol/day) is particularly necessary to prevent toxic 
megacolon.
Stool cultures for concurrent bacterial or amebic infection 
and C. difficile  toxin assay should be performed. If pathogens 
are detected, appropriate antibiotics must be administered. 
The prevalence of C. difficile  infection in patients with UC is 
three times higher than that in patients with non-IBD.102 C. 
difficile  infection shows four times higher mortality rate in 
patients with IBD than in other patients.103 Therefore, early 
Chang Hwan Choi, et al. • Second guidelines for the management of UC
16 www.irjournal.org
detection of C. difficile  toxin and adequate treatment are 
crucial in patients with severe UC.
Severe UC should be assessed with an early flexible sig-
moidoscopy with minimal air insufflation. Colonoscopy is 
contraindicated in patients with acute severe UC because of 
its possible adverse effects such as colon perforation or toxic 
megacolon.
Medications such as NSAIDs, antidiarrheal drugs, anti-
spasmodics, and narcotic analgesics need to be used cau-
tiously for severe UC because they can cause toxic megaco-
lon.104 Hemoglobin level must be maintained at ≥10 g/dL, 
and blood transfusion is performed if needed. 
It is critical to make an early decision for the subsequent 
therapy based on the response to intravenous corticoste-
roids. Delays in surgery or in providing second-line medical 
treatment for the patient who is unresponsive to intravenous 
corticosteroids may lead to worsening of clinical outcomes.105
Two main methods of assessing the treatment response of 
UC are stool frequency and serum CRP level.106-108 According 
to the Oxford criteria, nonresponse is defined as a CRP level 
of ≥45 mg/L and a stool frequency of three to eight times 
a day, or a stool frequency of >8 times a day after 3 days of 
treatment. These criteria correspond well to the need of col-
ectomy on the same admission.106,109 Studies have reported 
that severity assessed based on colonoscopic findings can 
predict corticosteroid treatment failure and surgery rates. 
However, because of the potential colon perforation risk, full 
colonoscopy is not recommended.110,111 Other indexes evalu-
ated on day 1 or 3 of hospitalization that have been reported 
to predict corticosteroid failure include ESR, albumin level, 
stool calprotectin level, and abdominal imaging findings. 
However, these indexes have limitations, and further stud-
ies are needed for validation.112,113 As these indexes are not 
definite, closer observation of the patient’s condition and 
cooperation with the surgeon are more important in making 
decisions about the treatment method and appropriate tim-
ing of the surgical intervention.
14. A normal diet or enteral nutrition is recommended for 
patients with moderate to severe UC (quality of evi-
dence, low; classification of recommendation, strong).
• Level of agreement: strongly agree 28.6%, agree 66.7%, 
uncertain 4.8%, disagree 0%, strongly disagree 0%
15. Total parenteral nutrition (TPN) is not effective as a pri-
mary treatment and only considered when enteral nutri-
tion is not possible in malnourished patients (quality of 
evidence, low; classification of recommendation, strong).
• Level of agreement: strongly agree 17.8%, agree 71.1%, 
uncertain 11.1%, disagree 0%, strongly disagree 0%
16. Antibiotics are not recommended when no evidence 
indicates infection (quality of evidence, moderate; clas-
sification of recommendation, strong)
• Level of agreement: strongly agree 32.6%, agree 54.4%, 
uncertain 8.7%, disagree 2.2%, strongly disagree 0%
No evidence supports that nil per os (NPO, nothing by 
mouth) diet improves the course of severe UC. A small-scale 
prospective study showed no clinical difference between a 
TPN group with NPO and an oral diet group.114-116 Total en-
teric nutrition with polymeric formula, which can be primary 
therapy for active CD, does not have therapeutic benefits 
for patients with UC. TPN with NPO is needed for patients 
who cannot receive orally or who have been scheduled to 
undergo colectomy.
Use of antibiotics in addition to corticosteroids has no ad-
ditional benefit over corticosteroid therapy alone. In a RCT 
with a small number of patients with severe UC who needed 
admission, no significant difference was found between the 
metronidazole or ciprofloxacin treatment group and the 
placebo treatment group.117-119 However, if a patient shows 
signs of sepsis or C. difficile  infection, administration of the 
appropriate antibiotic should be indicated.
2) Steroid-Refractory Moderate to Severe UC
17. Anti-TNF therapy is recommended for patients with 
moderate to severe UC who do not respond to cortico-
steroid therapy (quality of evidence, high; classification 
of recommendation, strong).
• Level of agreement: strongly agree 60.9%, agree 32.6%, 
uncertain 6.5%, disagree 0%, strongly disagree 0%
Anti-TNF agents such as infliximab, adalimumab, and 
golimumab are effective for remission induction and main-
tenance of moderate to severe UC. Meta-analyses of RCTs 
reported the effect of infliximab in patients who were using 
corticosteroids or unresponsive to corticosteroids.120-122 A 
meta-analysis of five studies showed that infliximab was 
more effective than placebo based on endoscopic findings 
(endoscopic remission failure RR, 0.72; 95% CI, 0.57−0.91; 
P=0.006).120 In the ACT-1 (n=364) and ACT-2 (n=364) stud-
ies, infliximab showed a higher clinical remission rate (RR, 
3.22; 95% CI, 2.18−4.76) and higher endoscopic remission 
rate (RR, 1.88; 95% CI, 1.54−2.28) than placebo.121
A RCT compared infliximab (n=24) and placebo (n=21) in 
patients with intravenous corticosteroid-refractory moder-
ate to severe UC. When the patients were assessed as having 
fulminant colitis after 3 days of treatment with intravenous 
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corticosteroid, infliximab was administered on the 4th day. 
When the patients had moderate to severe activities, inflix-
imab was administered on the 6th to the 8th day of treat-
ment. After 3 months, the placebo group had a higher rate of 
colectomy than the infliximab group (14 vs. 7: OR, 4.9; 95% 
CI, 1.4−17.0; P=0.017).123
A meta-analysis of the ULTRA 1 (n=390)92 and ULTRA 
2 (n=494)93 studies that investigated the effect of adalim-
umab on corticosteroid- or immunomodulator-refractory 
moderate to severe UC, adalimumab has shown to be more 
effective for remission induction than placebo (remission 
failure OR, 0.60; 95% CI, 0.42−0.86; P =0.006). In PURSUIT-
SC (n=774) of moderate to severe UC, golimumab treatment 
was associated with an 18% remission rate; and placebo, 
with 6% (P<0.0001).94
Evidence is insufficient to recommend a specific anti-TNF 
agent. In studies that compared between anti-TNF agents 
and placebo, the adverse effects of the treatments were not 
significantly different between the two groups, such as infu-
sion reaction, headache, rash, or arthralgia.120 However, con-
tinuous use of anti-TNF agents showed more adverse effects 
associated with sensitization. In addition, anti-TNF agents 
need to be used cautiously because it increases the risk of 
opportunistic infection.124,125
18. CMV infection must be verified in severe UC, which does 
not respond to intravenous corticosteroids. If infection 
is found, antiviral treatment (ganciclovir, 5.0−7.5 mg/
kg/12 hour) is recommended (quality of evidence, low 
or very low; classification of recommendation, strong).
• Level of agreement: strongly agree 36.2%, agree 61.7%, 
uncertain 2.1%, disagree 0%, strongly disagree 0%
In patients with UC treated with immunosuppressive 
therapy, reactivation of CMV is common. Therefore, if severe 
UC does not respond to the treatment, CMV infection must 
be identified. CMV colitis is related with poor prognosis 
and high risk of colectomy.126,127 In a prospective study, the 
prevalence of CMV infection among patients with severe UC 
and corticosteroid-resistant UC were 21% to 34%128 and 32% 
to 36%,129,130 respectively. In a Korean multicenter prospec-
tive study, the prevalence of CMV infection was 43% (31/72) 
among patients with moderate to severe UC and higher at 
67% (14/21) among those with corticosteroid-resistant UC. 
All 17 patients who were corticosteroid responsive did not 
need antiviral treatment. However, in 79% (11/14) of the pa-
tients who were corticosteroid resistant and had CMV infec-
tion, remission was induced after the antiviral treatment.131 
According to the Korean multicenter retrospective study 
that investigated the long-term prognosis of CMV infection 
in patients with moderate to severe UC, CMV-positive pa-
tients had significantly poor prognosis with high surgery and 
recurrence rates.132 Therefore, if the patient with moderate 
to severe UC does not respond to corticosteroid, the patients 
should be evaluated for CMV infection.
Diagnosis can be made through histopathology and im-
munohistochemistry by using tissue specimens collected 
from biopsy during sigmoidoscopy. CMV can be diagnosed 
when the H&E shows giant cells or intranuclear inclusion 
body. Diagnosis can also be made based on a positive result 
in CMV antigen immunohistochemical staining or viral DNA 
PCR. If a definite diagnosis is made, immunosuppressive 
therapy should be discontinued and 2 to 3 weeks of 5.0 to 7.5 
mg/kg ganciclovir treatment twice a day should be started.
19. Intravenous cyclosporine is considered for patients with 
severe UC that does not respond to intravenous corti-
costeroid (quality of evidence, low; classification of rec-
ommendation, weak).
• Level of agreement: strongly agree 6.1%, agree 71.4%, 
uncertain 20.4%, disagree 2.1%, strongly disagree 0%
20. Colectomy is considered if a patient with intravenous 
corticosteroid-refractory severe UC presents aggravation 
of clinical symptoms or does not respond to infliximab 
or cyclosporine treatment (quality of evidence, moder-
ate; classification of recommendation, strong).
• Level of agreement: strongly agree 50.0%, agree 47.6%, 
uncertain 0%, disagree 2.4%, strongly disagree 0%
Intravenous cyclosporine is effective for patients with 
severe UC, which does not respond to steroids. According 
to a small-scale RCT (n=20), 82% of patients who failed to 
respond to intravenous corticosteroid treatment showed 
response to 4 mg/kg/day intravenous cyclosporine within a 
mean treatment duration of 7 days. By contrast, none of the 
patients in the placebo treatment group showed response 
(RR, 0.18; 95% CI, 0.05−0.64; P<0.001).130 In a study that com-
pared the administration dosage of cyclosporine, 73 patients 
who failed to respond to steroid treatment were randomly 
assigned to cyclosporine 4 mg/kg and 2 mg/kg groups.131 
No difference in response rate was found on the 8th day of 
treatment (83% vs. 82%); however, a higher prevalence of 
hypertension was found in the 4 mg/kg group. Therefore, the 
currently recommended dosage is 2 mg/kg.
According to controlled studies and observational stud-
ies, 76% to 85% of patients responded to intravenous cyclo-
sporine treatment and avoided colectomy in a short-term 
period.130-134 However, a Cochrane review concluded that no 
clear evidence suggests that cyclosporine is more effective 
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than the standard treatment, as studies are limited by small 
sample sizes and no long-term results.135 In addition, cyclo-
sporine is not often clinically used because of its potential 
adverse effects and unfavorable long-term clinical outcomes 
in terms of surgery rate. The colectomy rate among patients 
responsive to cyclosporine was 20% after 1 year of treatment 
and 69% after 5 years of treatment.134,136 According to a retro-
spective analysis of long-term surgery rates after intravenous 
cyclosporine therapy for severe UC, the factors to avoid 
colectomy were a successful switching the treatment to oral 
thiopurine and naiveness to thiopurine prior cyclosporine 
therapy.134,137-139 Therefore, if the patient is unresponsive or 
have a failed past thiopurine treatment, cyclosporine treat-
ment may not be a good option.
The adverse effects of cyclosporine are hypertension, vom-
iting, hypokalemia, and hypomagnesemia. Caution should 
be exercised when using cyclosporines for hypocholesterol-
emia because grand mal seizure has been reported.
Tacrolimus is a calcineurin inhibitor that works through 
the same mechanism as does cyclosporine. It showed 
superior effect to placebo therapy in a RCT in severe UC 
patients.140 The response rates were 67% and 50% when the 
trough levels were 10 to 15 ng/mL and 5 to 10 ng/mL, re-
spectively, and 18% in placebo treatment. The weakness of 
this study is that the number of patients was too small. How-
ever, response to tacrolimus was similar with that response 
to 0.1 to 0.2 mg/kg oral cyclosporine and 0.01 to 0.02 mg/
kg intravenous cyclosporine in other case series.67,131,139 The 
long-term colectomy rate was 57% among the patients with 
UC treated with tacrolimus for 44 months.141
If the patient is not responsive to ≥3 days of intravenous 
corticosteroid therapy and to the subsequent 5 to 7 days 
of intravenous cyclosporine or infliximab therapy, surgery 
must be considered. Poor prognosis such as surgical compli-
cations or higher mortality rate during admission is related 
to delayed surgery in patients with severe UC. According to 
a study that analyzed data from a database of admitted pa-
tients around the United States, patients with severe UC who 
had surgery within 3 days of admission had lower mortality 
rate than those who had surgery after 6 days (OR, 2.12; 95% 
CI, 1.13−3.97) or 11 days (OR, 2.89; 95% CI, 1.41−5.91).142
3) Anti-tumor Necrosis Factor Therapy
21. Patients with infection should not receive biological 
therapy until the infection is controlled. Abscess must be 
drained before using biologics. Latent infections such as 
tuberculosis, hepatitis B, and human immunodeﬁciency 
virus must be excluded or treated before starting bio-
logical therapy. Patients inoculated with live vaccines 
should not receive biological therapy for 3 months 
(quality of evidence, very low; classification of recom-
mendation, weak).
• Level of agreement: strongly agree 26.1%, agree 65.2%, 
uncertain 6.5%, disagree 2.2%, strongly disagree 0%
Anti-TNF therapy increases the risk of severe infection 
in patients with rheumatic arthritis; however, the evidence 
is relatively poor in patients with IBD.143,144 The ACT-1 and 
ACT-2 studies, which are important studies about the effect 
of infliximab in patients with UC, showed no significant evi-
dence of serious infection risk related with anti-TNF thera-
py.90 However, meta-analysis reported that anti-TNF therapy 
raises the risk of opportunistic infection almost twice higher 
in patients with IBD. The risk increases when the patients 
received immunomodulators concomitantly.124
If the patient has active infection, anti-TNF therapy must 
be temporarily discontinued until the infection is controlled. 
In addition, C. difficile  infection must be excluded before 
starting anti-TNF therapy because it is related to higher risks 
of admission and mortality rate.145 The risk of pneumococcal 
infection is also increased in IBD patients with immuno-
suppressive therapy and the risk is higher in patients with 
advanced age or comorbidity. Therefore, pneumococcal 
vaccination in advance is recommended for IBD patients 
receiving anti-TNF therapy.20
Anti-TNF therapy is related with pneumocystis infection, 
and the risk is higher in patients with advanced age, un-
derlying pulmonary disorders, or concomitant use of high-
dose corticosteroid.146 Prophylactic administration of co-
trimoxazole is recommended if the patient is treated with 
triple immunosuppressants, including calcineurin inhibitors 
or anti-TNF agents. Co-trimoxazole administration should 
be also considered when the patient receives two kinds of 
immunosuppressants, including a calcineurin inhibitor. Co-
trimoxazole is administered 80 to 400 mg once a day or 160 
to 800 mg three times a week.145 Attenuated influenza vac-
cination should also be performed before or during the anti-
TNF therapy. When the patient has influenza, early antiviral 
treatment must be started.20
Anti-TNF therapy can reactivate latent tuberculosis.147 
Therefore, diagnosis and treatment of latent tuberculosis 
are important before starting anti-TNF therapy. To diagnose 
active and latent tuberculosis, history taking, physical ex-
amination, chest radiography, and tuberculosis infection test 
must be performed. All patients must go through chest radi-
ography to exclude asymptomatic active tuberculosis before 
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receiving anti-TNF agents. Fibrostreaky lesions on chest radi-
ography should be considered as spontaneous remission of 
tuberculosis, and treatment for latent tuberculosis must be 
initiated regardless of the tuberculosis infection result. How-
ever, when only small calcific nodules are observed on chest 
radiography, treatment for latent tuberculosis is unnecessary 
because of the low risk of live bacteria.148 If the patient had 
received adequate treatment for tuberculosis, treatment is 
not necessary regardless of fibrotic lesions.149
Tuberculin skin test (TST) and interferon-γ release assay 
(IGRA) are tests to detect tuberculosis infection. Diagnosis 
of latent tuberculosis in patients receiving anti-TNF follows 
the guidelines for immunosuppressed patients. Diagnosis 
can be made by using IGRA alone or in combination with 
TST. TST alone cannot be used as a diagnostic tool for latent 
tuberculosis.
In patients with active tuberculosis, anti-TNF therapy can 
be recommended after completion of tuberculosis treat-
ment. However, if the disease is a drug-sensitive tuberculosis 
with mild activity, anti-TNF therapy can be considered after 
2 months of intensive treatment. In case of latent tuberculo-
sis, anti-TNF therapy is usually recommended after 3 weeks 
of treatment; however, anti-TNF therapy can also be consid-
ered at the initial time of tuberculosis treatment. The stan-
dard regimen for latent tuberculosis is 9 months of isoniazid. 
However, 4 months of rifampicin therapy or 3 months of 
isoniazid/rifampicin combination therapy can be also rec-
ommended.103
Use of corticosteroids, immunomodulators, or anti-TNF 
therapy was related with hepatic dysfunction in 25% to 36% 
of patients with IBD and HBV infection, and more than 
half of the patients with HBV reactivation showed hepatic 
failure.150,151 Therefore, baseline studies for HBV infection, 
including HBsAg, anti-HBsAb, and anti-HBcAb, must be 
performed at the time of diagnosis. If HBV infection is con-
firmed, HBeAg, anti-HBeAb, and HBV-DNA tests must be 
performed. When both anti-HBsAb and anti-HBcAb are 
negative, vaccination should follow.145
Patients with IBD show decreased response to HBV vacci-
nation, which may be related with the disease itself and use 
of anti-TNF agents. Therefore, anti-HBsAb level must be as-
sessed after vaccination, and antibody titer should be moni-
tored in the high-risk group. The standard dose of vaccina-
tion may be insufficient in patients with IBD who were not 
previously vaccinated and are especially being treated with 
anti-TNF therapy. Repeated vaccination with double dose in 
0, 1, and 2 months can be given to the patient when no anti-
body is detected after the first vaccination schedule.152
Prophylactic antiviral treatment using nucleotide/nucleo-
side analogue is recommended in HBsAg-positive patients 
at least 2 weeks before immunosuppressive therapy and 
until 12 months after its termination. The presence of anti-
HBcAb and absence of HBsAg may be suggestive of latent 
infection. However, reactivation of the HBV during the im-
munosuppressive therapy is rare. Antiviral therapy is not 
necessary until HBV-DNA is detected. HBV-DNA should be 
checked every 2 to 3 months.
22. When starting anti-TNF therapy, combination therapy 
with thiopurine or methotrexate (MTX) rather than anti-
TNF monotherapy is recommended to induce remission 
(quality of evidence, moderate for AZA and very low for 
MTX; classification of recommendation, strong).
• Level of agreement: strongly agree 15.2%, agree 69.6%, 
uncertain 10.9%, disagree 4.4%, strongly disagree 0%
Effect of anti-TNF and AZA combination therapy was 
proved in the UC SUCCESS study. In anti-TNF-naive patients 
with moderate to severe UC, the remission rate without cor-
ticosteroid on the 16 weeks was higher in the com bination 
therapy group with 39.7% than in the infliximab mono-
therapy group with 23.7%.95 However, the mucosal healing 
rate and improvement of partial or total Mayo score were 
similar in both groups. In the ULTRA 1 study, the patients in 
the combination therapy group, who received adalimumab 
and immunomodulators without corticosteroid, showed 
the best therapeutic effect.92 The ULTRA 2 study revealed 
that antibody to adalimumab was detected less frequently 
in the combination therapy group than in the monotherapy 
group.93 In the PURSUIT study, although combination 
therapy with immunomodulator decreased the incidence of 
antibody to golimumab, no significant association was found 
between the serum golimumab level and the therapeutic ef-
fect.94
Experts concluded that combination therapy is preferred 
for thiopurine-naive patients when starting anti-TNF agents. 
However, the effect of combination therapy is not clear in 
patients unresponsive to previous thiopurine therapy.139 
Studies on the maintenance period of combination therapy 
are still insufficient.24 When the immunomodulator was 
withdrawn during the combination therapy, the factors as-
sociated with recurrence were higher levels of inflammatory 
markers, mucosal inflammation on endoscopic examina-
tion, shorter period of remission, and undetectable anti-TNF 
trough level.153
Although IBD itself does not increase the risk of infection, 
use of anti-TNF agents or thiopurine can increase the risk, 
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which can further increase with combination therapy.24 The 
occurrence rates of nonmelanoma skin cancer and other 
cancers are not increased by anti-TNF therapy. However, 
considering that the incidence is increased in combination 
therapy, the increased risk of cancer is more likely due to 
administration of immunomodulators.154 Especially patients 
aged >65 years have a higher risk of severe infection or lym-
phoproliferative disorders,136,137 whereas patients aged <35 
years who received thiopurine therapy for ≥2 year usually 
developed hepatosplenic T-cell lymphoma.138 By extrapolat-
ing the results of the study on rheumatoid arthritis, using 
MTX instead of AZA can be recommended in elderly pa-
tients, who have higher risks of developing nonmelanoma 
skin cancer and lymphoma.155
23. Evaluation of treatment response is recommended after 
8−12 weeks of anti-TNF therapy to determine the need 
to modify therapy (quality of evidence, low; classifica-
tion of recommendation, strong).
• Level of agreement: strongly agree 42.6%, agree 57.5%, 
uncertain 0%, disagree 0%, strongly disagree 0%
24. Anti-TNF dose escalation is recommended for remis-
sion induction when no sufficient response is achieved. 
Shortening the infusion interval of infliximab or elevat-
ing the dose to 10 mg/kg is recommended. The injec-
tion frequency of adalimumab is shortened to 1 week 
(quality of evidence, very low; classification of recom-
mendation, strong). 
• Level of agreement: strongly agree 25.6%, agree 58.1%, 
uncertain 16.3%, disagree 0%, strongly disagree 0%
In the RCTs that were assessed every 2 weeks after initia-
tion of treatments, significant symptomatic improvement 
was reported as early as 2 to 4 weeks with anti-TNF thera-
py.92-94 The research that compared the effect of anti-TNF 
therapy with that of placebo treatment for remission induc-
tion showed significantly higher remission rate with anti-
TNF therapy usually in the eighth week of treatment.90,92-94 
In the ULTRA 2 study, the symptom remission rate with 
adalimumab treatment was highest on the 16 weeks and 
started declining thereafter.93 Therefore, 8 to 12 weeks is an 
adequate period to assess the treatment effect of anti-TNF 
therapy. If no response is observed, the therapy should be 
modified. However, if the UC is severe, early assessment 
must be considered. However, no data on the optimum pe-
riod of endoscopic assessment are available yet.
Before determining the initial failure of the treatment in 
patients showing insufficient response to anti-TNF therapy, 
increasing the dosage must be considered first. The associa-
tions of high blood anti-TNF agent level with high remission 
and maintenance rates ware proved in RCTs.156 Moreover, 
high trough level was associated with high mucosal healing 
rate.157,158 The methods of drug dose elevation for remission 
induction include increasing the dose and shortening the 
admission period.
4) Other Biological Therapies
25. In patients who have primary nonresponse in remission 
induction with anti-TNF, vedolizumab treatment may 
be more effective than switching to another anti-TNF 
agent (quality of evidence, very low; classification of 
recommendation, weak).
• Level of agreement: strongly agree 2.0%, agree 73.5%, un-
certain 20.4%, disagree 4.1%, strongly disagree 0%
26. In patients with loss of secondary response to anti-
TNF, different types of anti-TNF agents or vedolizumab 
treatment is recommended based on therapeutic drug 
monitoring (quality of evidence, very low; classification 
of recommendation, strong).
• Level of agreement: strongly agree 17.4%, agree 73.9%, 
uncertain 6.5%, disagree 2.2%, strongly disagree 0%
27. Vedolizumab is considered for remission induction 
when moderate to severe UC fails to respond to corti-
costeroids, thiopurine, or anti-TNF (quality of evidence, 
moderate; classification of recommendation, strong).
• Level of agreement: strongly agree 4.4%, agree 80.4%, un-
certain 10.9%, disagree 4.4%, strongly disagree 0%
28. Evaluation of treatment response is recommended after 
8−14 weeks of vedolizumab therapy to determine the 
need to modify therapy (quality of evidence, very low; 
classification of recommendation, strong).
• Level of agreement: strongly agree 26.7%, agree 71.1%, 
uncertain 2.2%, disagree 0%, strongly disagree 0%
Dose escalation is the first strategy to consider in patients 
with inadequate response to anti-TNF therapy. This should 
be decided based on therapeutic drug monitoring. Studies 
are lacking on whether to change the treatment to other anti-
TNF agents or to vedolizumab in patients who have failed 
to respond despite the dose elevation. According to studies, 
changing the type of anti-TNF agent can be more effective 
for patients who test positive for antidrug antibody. When 
the patient has a history of primary nonresponse, it will be 
less effective.157,159,160
A recent study showed that in patients with primary non-
response to anti-TNF therapy, changing the treatment to 
vedolizumab had better long-term result than changing the 
type of anti-TNF agent. In a study of 99 patients with primary 
nonresponse to infliximab and no history of receiving other 
anti-TNF medications, the patients who received vedolizum-
ab showed numerically lower cumulative recurrence rate 
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(log-rank, P =0.080) than those who changed to a different 
anti-TNF agent.161
As vedolizumab works in a different mechanism with 
anti-TNF medication, it can be effective for patients with 
either primary or secondary anti-TNF therapy failure. In 
the GEMINI I study, 374 patients who used corticosteroid, 
immunomodulator, or anti-TNF agent in the past were ran-
domized into the vedolizumab or placebo group.162 On the 
6 weeks of treatment, vedolizumab showed a significantly 
higher remission rate than placebo (16.9% vs. 5.4%; P=0.001). 
When the result was analyzed by dividing them further into 
groups according to the previous medications, no statisti-
cally significant difference was found, but vedolizumab 
showed numerically better remission rate: anti-TNF (9.8% vs. 
3.2%), corticosteroids (21.4% vs. 0%), or immunomodulators 
(21.9% vs. 10.9%).162 Clinical response rate was significantly 
higher in the vedolizumab group (47.1% vs. 25.5%; P<0.001). 
The clinical response rate of vedolizumab was also higher in 
the groups that had treatment failure with anti-TNF agents 
(39.0% vs. 20.6%) or corticosteroids (59.5% vs. 20.0%).162 
Mucosal healing rate was higher in the vedolizumab group 
than in the placebo group (59.5% vs. 24.0%) among the pa-
tients who had failed corticosteroid treatment.162 In phase 
2 RCT, the clinical response rate of the vedolizumab group 
was approximately twice that of the placebo group (>50% vs. 
22%−33%).163 No significant difference in the proportion of 
patients who experienced more than one adverse event dur-
ing the remission induction treatment was found between 
the vedolizumab and placebo groups (40% vs. 46%). Howev-
er, the vedolizumab group had a lower proportion of patients 
who experienced severe adverse events (2% vs. 7%).162 The 
most common adverse events associated with vedolizumab 
treatment were headache, aggravation of UC, and infection. 
Therefore, vedolizumab therapy can be a useful treatment 
option for patients with failed corticosteroid, immunomodu-
lator, or anti-TNF therapy. No studies have been conducted 
on the treatment strategy after vedolizumab treatment fail-
ure, but anti-TNF agents can be considered. In the GEMINI I 
study, no significant differences were found between 4- and 
8-week treatment intervals in vedolizumab maintenance 
treatments.162
In the GEMINI I study, vedolizumab treatment showed 
significantly higher symptomatic response rate on the 6 
weeks of treatment than placebo treatment (47.1% vs. 25.5%; 
95% CI, 11.6−31.7; P<0.001).162 Improvement of partial Mayo 
score was highest on the 6 weeks. Thereafter, no further im-
provement in Mayo score was observed, and a similar effect 
continued during the maintenance treatment period. There-
fore, assessment of vedolizumab treatment is recommended 
in the 8th−14th week, which is before the start of the mainte-
nance treatment.
3. Other Treatments 
1) Methotrexate
Prospective studies on the effect of MTX on UC are lack-
ing, and the results are not consistent because of the vari-
ance of medication dosages or administrating methods.164-166 
According to a RCT, the effect of MTX therapy was not 
superior to that of placebo treatment in steroid-dependent 
patients when used at 12.5 mg per week by oral administra-
tion.164 A Cochrane review concluded that evidence is insuf-
ficient to recommend MTX therapy to UC patients.166
2) Probiotics
Evidences are inadequate to support the use of probiotics 
in UC treatment. In a meta-analysis of 23 RCTs that inves-
tigated the effect of probiotics on UC, CD, and pouchitis, 
the remission rate in the probiotics group was higher than 
that in the placebo group (RR, 1.80; P<0.0001). However, the 
result of the subgroup analysis showed a significant effect 
only in VSL#3 (RR, 1.74; P =0.004).167 In a meta-analysis of 
three RCTs that investigated VSL#3 effects on UC, the group 
that received additional VSL#3 in the conventional therapy 
showed a higher remission rate than the group that received 
the conventional therapy alone (43.8% vs. 24.8%: OR, 2.4; 
95% CI, 1.48−3.88; P =0.0001).168 However, the quality of the 
studies included in the meta-analysis was not good enough. 
Therefore, it is difficult to recommend probiotics as remis-
sion induction treatment for UC.
In a meta-analysis of RCTs about the effect of Escherichia 
coli (E. coli) Nissle 1917 on UC, it did not show better effect 
on remission induction than placebo but showed a similar 
effect on remission maintenance with the 5-ASA treat-
ment.167,169,170 Therefore, when 5-ASA cannot be used for 
remission maintenance treatment because of its adverse ef-
fect, E. coli  Nissle 1917 can be considered as the alternative 
treatment.
MAINTENANCE OF REMISSION
The goal of maintenance therapy for patients with UC is 
to maintain clinical and endoscopic remission without us-
ing corticosteroids. In addition, it is aimed at controlling the 
symptoms, improving patients’ quality of life, and prevent-
ing colon cancer development and improving its long-term 
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prognosis.
According to a recent meta-analysis of RCTs, among the 
patients with UC who are in inactive or remission status, 
60% of the nontreated patients had a disease relapse re-
gardless of the extent of the disease.171 Therefore, remission 
maintenance therapy is recommended to all patients with 
UC. Things to consider when choosing the treatment for re-
mission maintenance are extent and activity of the disease, 
safety of the treatment agents, and prevention of colon can-
cer. Frequency of recurrence, medications used at the recent 
relapse, and adherence to the medications must also be con-
sidered in maintenance therapy.172
1. 5-Aminosalicylic Acids
29. Oral 5-ASA is recommended as the first-line mainte-
nance therapy in patients who respond to oral/topical 
5-ASA or corticosteroids (quality of evidence, high; 
classification of recommendation, strong).
• Level of agreement: strongly agree 68.9%, agree 31.1%, 
uncertain 0%, disagree 0%, strongly disagree 0%
30. Topical 5-ASA (suppository or enema) can be used as 
maintenance therapy for proctitis or left-sided colitis 
(quality of evidence, high; classification of recommen-
dation, strong).
• Level of agreement: strongly agree 60.9%, agree 37.0%, 
uncertain 2.2%, disagree 0%, strongly disagree 0%
31. Combination therapy is more effective than oral or top-
ical 5-ASA monotherapy. In case of recurrence with oral 
or topical 5-ASA monotherapy, combination therapy is 
recommended (quality of evidence, moderate; classifi-
cation of recommendation, strong).
• Level of agreement: strongly agree 67.4%, agree 32.6%, 
uncertain 0%, disagree 0%, strongly disagree 0%
32. At least 2 g/day of oral 5-ASA is recommended for 
maintenance of remission (quality of evidence, moder-
ate; classification of recommendation, strong).
• Level of agreement: strongly agree 35.6%, agree 62.2%, 
uncertain 0%, disagree 2.2%, strongly disagree 0%
33. The 5-ASA dose can be adjusted for maintenance of 
remission based on the case. High-dose oral 5-ASA 
therapy (≥3.0 g/day) can be useful in patients such 
as extensive colitis or frequent relapse (quality of evi-
dence, low; classification of recommendation, weak).
• Level of agreement: strongly agree 19.6%, agree 73.9%, 
uncertain 6.5%, disagree 0%, strongly disagree 0%
34. In patients with topical 5-ASA-induced remission, the 
same therapy can be used to maintain remission. It can 
also be used by divided dosing of 3 g of topical 5-ASA 
per week (quality of evidence, very low; classification 
of recommendation, weak).
• Level of agreement: strongly agree 18.4%, agree 77.5%, 
uncertain 4.1%, disagree 0%, strongly disagree 0%
35. The effects of taking oral 5-ASA once a day and tak-
ing the same dosage with frequent administration are 
similar for maintenance of remission. Therefore, dosing 
frequency can be determined according to the patients’ 
preference and compliance (quality of evidence, high; 
classification of recommendation, strong).
• Level of agreement: strongly agree 44.9%, agree 55.1%, 
uncertain 0%, disagree 4.6%, strongly disagree 0%
Oral 5-ASA is the first-line maintenance therapy for pa-
tients who respond to oral/topical 5-ASA or corticosteroids, 
and various studies have reported that oral 5-ASA is an effec-
tive maintenance therapy.173-179
A meta-analysis of 11 RCTs showed that the relative risk 
of recurrence was significantly lower in patients treated 
with 5-ASA than in those treated with placebo (0.65; 95% CI, 
0.55−0.76) among patients with quiescent UC.59 In addition, 
a meta-analysis of seven clinical trials also showed that the 
recurrence rate was lower in the 5-ASA maintenance group 
with 41% than in the placebo group with 58% (RR, 0.69; 95% 
CI, 0.62−0.77).171 However, no significant difference in the in-
cidence of adverse event was found between the oral 5-ASA 
and placebo groups. Topical 5-ASA (suppository or enema) 
are effective for maintenance of remission in proctitis or 
left-sided colitis. A meta-analysis of seven RCTs showed a 
significantly lower relative risk of relapse in the topical 5-ASA 
group (6−24 months) than in the placebo group (0.60, 95% 
CI, 0.49−0.73).180 In addition, in a meta-analysis of four RCTs, 
the 12-month clinical remission rate in the topical 5-ASA 
group was significantly higher than that in the placebo group 
(62% vs. 30%; RR, 2.22; 95% CI, 1.26−3.90; P<0.01).181 A recent 
meta-analysis also reported that 5-ASA had significantly low-
er rates of clinical or endoscopic remission failure (OR, 0.47; 
95% CI, 0.36−0.62 with a number needed to treat of 6).173
RCTs have been conducted on combination therapy with 
oral and topical 5-ASA. Remission maintenance rate was 
significantly higher in the combination therapy group than 
in the oral 5-ASA only group.38,182 Therefore, combination 
therapy can be considered for relapse with oral or topical 
5-ASA monotherapy.
Ten RCTs compared two or three different dosages of 
oral 5-ASA for maintenance therapy.67,140,172,179,183-188 In three 
studies, remission maintenance rates (recurrence rates) 
did not significantly differ according to dosage,67,140,186 but 
seven studies showed significant differences between dose 
groups.172,179,183-185,187,188 Each study varied in maximum oral 
5-ASA dosage, from 1.2 to 4.8 g/day. Among six studies that 
used ≥2.0 g/day of oral 5-ASA as maximum dosage, five 
showed better effect in the higher-dose group,67,172,179,183,186,187 
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three studies used ≥3.0 g/day of oral 5-ASA as maximum 
dose. When this dose was compared with 5-ASA doses of 
1.5, 1.5, and 2.4 g/day, respectively, two studies showed sig-
nificantly higher remission maintenance rate (P <0.05) and 
one study showed a higher tendency in the high-dose group 
(P =0.057).178,182,186 In another study, when the patients had 
mild inflammation on the endoscopic finding at the start of 
the maintenance therapy, high-dose (3.0 g/day vs. 1.5 g/day) 
therapy was found to be more effective.179 In yet another study, 
high-dose (4.8 g/day vs. 2.4 g/day) treatment showed better 
effect when used for extensive colitis, young patients aged <40 
years, or patients with frequent relapses.187 Therefore, using an 
oral 5-ASA dosage of ≥2.0 g/day for remission maintenance is 
recommended, and using a high dosage of ≥3 g/day for main-
tenance therapy can be useful for patients with extensive coli-
tis or frequent relapses. The use of high-dose 5-ASA did not 
significantly increase the incidence of adverse events when 
compared with low or standard doses.67,140,172,179,183-188
Previous studies reported that taking oral 5-ASA once a 
day and taking the same dose twice or three times a day had 
a similar effect on remission maintenance.68,175,179,189 In addi-
tion, a meta-analysis of seven RCTs showed no significant 
difference in recurrence rate (RR, 0.94; 95% CI, 0.82−1.08)59 
and adverse effect between once-daily dosing and divided 
dosing.58,66,184 Several studies have reported no significant dif-
ferences in adherence between oral 5-ASA once-daily dosing 
and divided dosing.58,59,66,184 However, a recent study with 362 
patients who received oral 5-ASA reported that the 1-year 
remission rate was 12% higher in the once-daily dosing 
group than in the twice-daily divided dosing group (73.8% 
vs. 63.6%). Adherence to the medication was significantly 
higher in the patients who received once-daily dosing than 
in those who received divided dosing.189 In addition, other 
studies reported that taking oral 5-ASA in once-daily dosing 
is more preferred by patients than taking it in divided dosing 
for remission maintenance.67,68
2. Thiopurines
36. AZA or 6-MP is recommended to patients with UC 
with early or frequent relapses, who are unable to take 
5-ASA, or who are already taking adequate dosage of 
5-ASA (quality of evidence, very low; classification of 
recommendation, weak).
• Level of agreement: strongly agree 15.6%, agree 73.3%, 
uncertain 11.1%, disagree 0%, strongly disagree 0%
37. In patients with UC who showed clinical remission with 
corticosteroid, thiopurine therapy can be used to maintain 
remission without corticosteroids (quality of evidence, 
low; classification of recommendation, weak).
• Level of agreement: strongly agree 19.6%, agree 63.0%, 
uncertain 15.2%, disagree 2.2%, strongly disagree 0%
38. Thiopurine is recommended to patients with corticoste-
roid-dependent UC (quality of evidence, high; classifi-
cation of recommendation, strong).
• Level of agreement: strongly agree 48.7%, agree 51.4%, 
uncertain 0%, disagree 0%, strongly disagree 0%
39. Thiopurine is recommended to maintain remission 
when cyclosporine or tacrolimus was used for remission 
induction (quality of evidence, low; classification of 
recommendation, weak).
• Level of agreement: strongly agree 14.3%, agree 77.5%, 
uncertain 8.2%, disagree 0%, strongly disagree 0%
AZA or 6-MP can be effective for patients who are unre-
sponsive to or intolerant of 5-ASA, or are corticosteroid de-
pendent.24 AZA or 6-MP should be considered for remission 
maintenance when >2 episodes of disease flare up requiring 
corticosteroid treatment for 12 months or when 5-ASA can-
not maintain the remission state. AZA or 6-MP can be used 
initially to maintain remission in severe UC, and 5-ASA can 
be used if either medication is contraindicated.109 Meta-
analysis studies reported that AZA is effective in remission 
maintenance of UC patients.190-192 Sixty-five percent of pa-
tients failed to maintain remission with the placebo, whereas 
44% of patients failed with AZA treatment.192
An RCT showed that AZA was significantly more effective 
than 5-ASA in maintaining clinical and endoscopic remis-
sion and avoiding corticosteroid requirement for a 6-month 
follow-up period in the treatment of steroid-dependent UC 
(53% vs. 21%).80 A Korean study also showed that the 3-year 
remission maintenance rate in corticosteroid-dependent UC 
patients was 25.0% in the AZA-intolerant group and 71.2% in 
the AZA-treated group.193
Calcineurin inhibitors such as cyclosporine or tacrolimus 
can be used as salvage therapy for corticosteroid-refractory 
patients with UC.194 AZA or 6-MP is more effective than 5-ASA 
monotherapy in maintaining remission and preventing col-
ectomy when cyclosporine was used for remission induction 
in patients with severe corticosteroid-refractory UC.133,195-197 In 
a retrospective study, colectomy is required in 45% of the pa-
tients in the cyclosporine monotherapy group and only 20% 
of the patients in the AZA or 6-MP group among initial cyclo-
sporine responders.133 Oral cyclosporine is usually used until 
thiopurines show effects, but switching to thiopurines without 
using oral cyclosporine is another option.198 Oral cyclosporine 
is generally not used for >6 months because of the long-term 
adverse effect such as nephrotoxicity.
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The recommended dose of AZA is 2.0 to 2.5 mg/kg/day, 
and that of 6-MP is 1.0 to 1.5 mg/kg/day.98,199 One of the most 
important limitations and serious adverse effects of thiopu-
rines is leukopenia. Leukopenia occurs only in 5% of Cauca-
sians.200-202 However, it is more common in Asians. According 
to a Korean multicenter study, among 278 patients who 
received a mean AZA dosage of 1.8 mg/kg/day, 110 (39.6%) 
developed leukopenia.203 Two Japanese studies that used co-
horts with wild-type TPMT  (thiopurine S-methyltransferase) 
genes showed that leukopenia developed in 18 of 114 pa-
tients (15.8%) and 7 of 70 patients (10.0%) even though only 
AZA 50 mg/day was administered.204,205 A Chinese study also 
showed that 36 of 199 patients (18.1%) developed leukopenia 
(<3,500/mm3).206 Considering that most of East-Asian studies 
used lower doses of AZA than recommended, more frequent 
and severe leukopenia is expected with the standard dose of 
thiopurines.24
A stepwise increase in thiopurine dose for several months 
is usually preferable to starting with the target dose in East-
Asians.24 The best way to reach the target dosage is not 
known yet. However, starting from 50 mg and increasing 
the dosage by 25 mg every 2 to 4 weeks while monitoring 
adverse effects such as leukopenia is commonly used. Based 
on the survey of clinical practice patterns in the treatment 
of IBD in Korea, 80% of the responders started AZA therapy 
at 50 mg/day, 68% increased the dose by 25 mg, and 56% 
increased the dose every 4 week.15 However, it may delay the 
time to clinical response, although thiopurine-induced my-
elotoxicity can be decreased.207
Assessment of the TPMT  genotype or enzyme activity 
before using thiopurines has limited value in East-Asian pa-
tients. The TPMT mutation rate is lower in Asians (1%−3%) 
than in Caucasians (10%). Nevertheless, Asian patients 
show a higher incidence of thiopurine-induced leukopenia. 
Among Asians who show thiopurine-induced leukocytope-
nia, the percentage of those with TPMT mutation is only 0% 
to 5.6%.24 Assessment of the NUDT15  (nucleoside diphos-
phate-linked moiety X motif 15) genotype may be more use-
ful in predicting thiopurine-induced early leukopenia. In Ko-
reans, a nonsynonymous single-nucleotide polymorphism of 
the NUDT15 gene mutation was found to be a risk factor of 
thiopurine-induced early leukopenia. The frequency of the 
NUDT15 risk allele is much higher in East Asians (Koreans, 
10.4%; Japanese, 7%; Chinese, 13%; and admixed American 
population, 2%).208
Monitoring of complete blood count is necessary for all 
patients with UC treated with thiopurines. Severe leukopenia 
usually occurs at the early phase of the treatment.209 Accord-
ing to a study, the incidence of severe leukopenia (<1,000/
mm3) was highest within the first 8 weeks of thiopurine thera-
py and the median time to first documentation of severe leu-
kopenia was 24.5 days.210 No consensus has been reached on 
the optimal frequency of complete blood count tests.141 How-
ever, monitoring once every 2 weeks for the first 2 months 
and then every 4 to 12 weeks is a preferred schedule.24
Bone marrow toxicity must be cautioned when thiopurine 
is combined with oral 5-ASA. Combination therapy with 
5-ASA and thiopurines increases the serum level of 6-thio-
guanine,211,212 which is the active metabolite of thiopurines. 
The combination therapy has a higher rate of myelotoxicity 
compared with thiopurine monotherapy.211,213
Evidences are insufficient to determine when thiopurines 
can be discontinued.24 The recurrence rate of UC after cessa-
tion of AZA is 35% to 77% after 1 year and 65% to 75% after 5 
years.164,202,214 Duration of AZA maintenance was not related 
to the recurrence rate after treatment cessation, and pro-
longed or indefinite use of thiopurines may be considered 
for remission maintenance.202 Usually, thiopurine is used for 
at least 18 months after remission and can be maintained for 
≥4 years.24 Thiopurines are frequently discontinued because 
of adverse events such as nausea, hepatotoxicity, myelotox-
icity, and pancreatitis. Overall, 10% to 28% of patients experi-
ence adverse effects, of whom 50% to 80% are required to 
discontinue the medication.165
Use of thiopurines increases the risk of lymphoma and 
nonmelanoma skin cancer, but the absolute risk of malignan-
cy is low.24 According to a meta-analysis of eight population-
based studies, the standardized incidence ratio of lymphoma 
was increased to 5.71 (95% CI, 3.72−10.1) in patients with 
UC treated with thiopurine but was 1.42 (95% CI, 0.86−2.34) 
in patients who discontinued thiopurine.215 In a recent meta-
analysis that involved ≥60,000 patients with IBD, the pooled 
adjusted hazard ratio of nonmelanoma skin cancer after 
using thiopurines was 2.28 (95% CI, 1.50−3.45).216 However, 
the result of this meta-analysis should be interpreted care-
fully because of the marked heterogeneity between the 
studies. Whether the modestly increased risk of lymphoma 
and nonmelanoma skin cancer should be considered prior 
to the benefits of thiopurines in the treatment of IBD is still 
unclear.216,217
3. Biologics
40. Anti-TNF therapy is recommended to corticosteroid-
dependent patients with UC (quality of evidence, very 
low; classification of recommendation, strong).
• Level of agreement: strongly agree 31.1%, agree 57.8%, 
uncertain 8.9%, disagree 2.2%, strongly disagree 0%
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Patients who require corticosteroid therapy have higher 
risks of relapse and colectomy than patients who do not need 
it.183,218,219 Considering the adverse events associated with cor-
ticosteroid use, the ultimate goal of UC treatment is to main-
tain the remission state without corticosteroid use.97,98,220
Most patients in RCTs of anti-TNF therapy did not respond 
to corticosteroids or were using corticosteroids at the time 
of the study.92-94,120 In these studies, anti-TNF therapy showed 
the effect of reducing corticosteroid use. In the ACT-1 and 
ACT-2 studies, 60% of the patients were using corticoste-
roids at the time of infliximab therapy and 30% showed 
resistance to corticosteroids. The infliximab group showed 
a significantly higher remission rate than the placebo group 
(20%−30% vs. 3%−10% at week 30).90 In addition, the remis-
sion rate was similar in both groups regardless of corticoste-
roid resistance. In the ULTRA 2 study, corticosteroid therapy 
could be stopped at 16 weeks of treatment in 31% of the 
adalimumab therapy group and in 18% of the placebo group. 
This effect was maintained through 52 weeks.93 In PURSUIT 
study of maintenance therapy, 54% of the patients were us-
ing corticosteroids at the time of the treatment, and 25% of 
the patients in the golimumab group and 18% of the patients 
in the placebo group maintained remission without using 
corticosteroids at 54 weeks of treatment.221
AZA therapy can be recommended if the patient has 
reached clinical remission with corticosteroid therapy. How-
ever, in corticosteroid-dependent patients, combination 
therapy with anti-TNF agent can be a better option. In the 
SUCCESS study, anti-TNF therapy showed higher a mucosal 
healing rate than AZA therapy.95
41. Continuous anti-TNF therapy is recommended for re-
mission maintenance in patients with remission induced 
by anti-TNF agents (quality of evidence, very low for 
infliximab and adalimumab, high for golimumab; clas-
sification of recommendation, strong).
• Level of agreement: strongly agree 56.5%, agree 43.5%, 
uncertain 0%, disagree 0%, strongly disagree 0%
In the ACT-1 study, the 1-year remission rate was higher 
in the infliximab group with 35% than in the placebo group 
with 16%.90 In the prolongation study of ACT-1 and ACT, 
90% of the infliximab-responsive patients showed clinical 
remission maintenance with up to 3 years of therapy.222 The 
cumulative colectomy rate on 54 weeks of treatment in the 
ACT-1 and ACT-2 studies was 10% in the infliximab group 
and 17% in the placebo group. Infliximab administration 
showed a 7% reduction in surgery rate.223
The ULTRA 2 study reported a similar result. Among the 
patients who showed clinical response after 8 weeks of adali-
mumab administration, the remission rate at 52 weeks of 
treatment was 31%.224 In a study that analyzed the treatment 
effect of adalimumab therapy by prolonging the ULTRA 1 
study until 52 week, 38.8% of the patients who showed re-
sponse in the 8 weeks of treatment maintained complete 
remission at 52 weeks.225 The PURSUIT study randomized 
the patients who showed response to golimumab induction 
treatment into golimumab and placebo groups. The group 
that continued golimumab therapy showed a higher remis-
sion rate at 54 weeks of treatment than the placebo group 
(23%−28% vs. 15.6%; P=0.004).221
Anti-TNF therapy is associated with an increased risk of 
opportunistic infection, particularly when used as combi-
nation therapy, especially with corticosteroid or immuno-
modulator. However, the absolute risk is low.124,125,226 In a 
meta-analysis with 22 RCTs, the occurrence of opportunistic 
infection was higher in the anti-TNF-treated group with 
0.9% (39/4,135) than in the placebo-treated group with 0.3% 
(9/2,919; RR, 2.05; 95% CI, 1.10−3.85) in patients with IBD.124 
Patients with mycobacterium tuberculosis infection (n=8), 
herpes simplex infection (n=8), oral or esophageal candidia-
sis (n=6), herpes zoster infection (n=6), varicella-zoster in-
fection (n=2), CMV or Epstein-Barr virus infection (n=2), and 
Nocardia infection (n=1) were included among the patients 
treated with anti-TNF agents. The risk of tuberculosis infec-
tion increased 2.5 times higher in the patients with anti-TNF 
therapy.124 A meta-analysis of 22 RCTs that compared the 
incidence of malignancy in patients with IBD showed no sig-
nificant difference between the anti-TNF group with 0.39% 
(16/4,135) and the placebo group with 0.45% (13/2,919; RR, 
0.77; 95% CI, 0.37−1.59).226 No occurrence of lymphoma was 
observed in the anti-TNF group, and three patients were 
diagnosed as having lymphoma in the placebo group. It ap-
pears that anti-TNF therapy does not increase the risk of 
malignancy up to 1 year of use.
No study has been conducted on the difference of clinical 
effect among anti-TNF agents. Therefore, anti-TNF agents 
used for remission induction should be continuously used 
for remission maintenance.90,221,222,224,225 Studies about long-
term effect of anti-TNF therapy are lacking. Therefore, con-
tinuing the therapy until loss of response is recommended. 
However, the patient should be informed about the risks and 
safety problems when an anti-TNF agent is used in a com-
bination therapy, especially with corticosteroid or immuno-
modulator.
Chang Hwan Choi, et al. • Second guidelines for the management of UC
26 www.irjournal.org
42. To recapture remission, dose escalation of the anti-TNF 
agent is recommended when the response disappears 
during the remission maintenance (quality of evidence, 
very low; classification of recommendation, strong).
• Level of agreement: strongly agree 21.7%, agree 69.6%, 
uncertain 8.7%, disagree 0%, strongly disagree 0%
A secondary loss of response during the anti-TNF main-
tenance therapy can be the result of inadequate drug levels 
and may be due to the production of antidrug antibod-
ies.222,227 A retrospective study was performed to understand 
the reasons for the loss of response or partial response. Se-
rum levels of anti-TNF agents were measured in the study. 
In 45% of the patients, the serum level of the agent was 
lower than the needed level. In 17% of the patients, antibody 
against the agent was detected.159 Eighty-six percent of the 
patients who had subtherapeutic concentrations showed 
response to the anti-TNF agent when the dosage was in-
creased. However, only 17% of the patients who had antidrug 
antibody showed an effect of the drug. In a prospective study 
with UC patients who had a recurrence during the adalim-
umab maintenance therapy, 67% of the patients who tested 
negative for antidrug antibody and had subtherapeutic anti-
TNF agent concentrations showed effective response when 
the medication dosage was increased. However, the patients 
who had antidrug antibody against the anti-TNF agent and 
had low trough levels, increasing the anti-TNF agent dos-
age showed no response.160 Even though the study was not 
about UC, a study on patients with CD who lost response 
during the infliximab treatment showed that when the inflix-
imab administration interval was shortened from 8 weeks to 
4 weeks, 83% of the patients showed response at 54 weeks 
of treatment. This showed a relationship between clinical 
efficacy and serum trough level.158 Therefore, before making 
a decision about anti-TNF treatment failure, increasing the 
dosage is needed. Moreover, assessing both serum level of 
the anti-TNF agent and the presence of antibody against the 
agent can be useful.
43. Therapeutic drug monitoring is recommended to opti-
mize the anti-TNF agent dosage (quality of evidence, 
low; classification of recommendation, strong).
• Level of agreement: strongly agree 32.6%, agree 63.0%, 
uncertain 4.4%, disagree 0%, strongly disagree 0%
Studies that used anti-TNF agents reported the nega-
tive effect of low trough level and the antibody production 
on the therapeutic effects. These show the importance of 
therapeutic drug monitoring when making treatment deci-
sions.94,156-158,160,227 Therefore, therapeutic drug monitoring 
needs to include serum trough level assessment and anti-
body titration of the agent.
In RCTs of maintenance therapy using anti-TNF agents, 3% 
of patients treated with golimumab for 1 year and 15% of the 
patients treated with infliximab for 3 years showed positive 
for antidrug antibody.94,222 Among the patients with loss of re-
sponse to anti-TNF therapy, 20% had antidrug antibody.159,160 
Even though the antibody reaction can be temporary and 
does not always relate to negative effects, an association was 
found with permanent loss of response when the antibody 
titration was continuously high.227
In a study of infliximab maintenance therapy for patients 
with secondary loss of response, the increased serum trough 
level after dose intensification was a strong predictive factor 
of mucosal healing.228 In a prospective study that analyzed 
the effect of therapeutic drug monitoring in patients who 
have partial or complete loss of response, dose intensifica-
tion was more effective than changing the type of anti-TNF 
agent when the serum trough level was low. On the contrary, 
when antidrug antibody was present, changing the type of 
anti-TNF agent was more effective.159 In a prospective cohort 
study of patients with secondary loss of response, 90% of the 
patients showed treatment failure even with a different type 
of anti-TNF agent when their serum trough level was high.160 
Therefore, therapeutic drug monitoring can be useful in 
making treatment decisions for patients with secondary loss 
of response.
44. Continuous use of vedolizumab is recommended for 
remission maintenance in patients with vedolizumab-
induced remission (quality of evidence, moderate; clas-
sification of recommendation, strong).
• Level of agreement: strongly agree 43.5%, agree 54.4%, 
uncertain 2.2%, disagree 0%, strongly disagree 0%
In the GEMINI I study, patients who responded to vedoli-
zumab therapy (n=373) were randomized into groups of 
vedolizumab every 4 weeks, vedolizumab every 8 weeks, 
and placebo for maintenance treatment. On the 52 weeks 
of treatment, the vedolizumab groups showed significantly 
higher remission rates than the placebo group (44.8% and 
41.8% vs. 15.9%; P<0.001).162 In a study of patients with failed 
corticosteroid treatment in the past, vedolizumab therapy 
showed a significantly higher long-term mucosal healing rate 
than placebo (60.0% and 68.4% vs. 26.9%).15 No significant 
difference in effect was found between the groups treated 
with vedolizumab every 4 and 8 weeks.162 In another study, 
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when vedolizumab was maintained for up to 78 weeks, 60% 
of the patients maintained remission and no specific adverse 
effect was observed during the long-term period.229
Six vedolizumab studies reported no association between 
vedolizumab treatment and the occurrence of infection or 
severe adverse events (n=2,830; exposure range, 1−1,977 
days). Adverse effects such as severe clostridium infection, 
sepsis, and tuberculosis infection were rarely found (≤0.6%), 
and none of the patients had progressive multifocal leu-
koencephalopathy.230 Clinically meaningful infusion reac-
tion was also rarely found. Infusion reaction that is severe 
enough to discontinue vedolizumab treatment was found 
in three patients in the GEMINI 1 study and in one patient 
in the GEMINI 2 study. Immune response to the agent was 
also rarely found. According to the GEMINI 1 study, which 
monitored patients for 52 weeks, among 620 patients, only 
3.7% showed a positive result for antivedolizumab antibody 
during the remission induction and maintenance periods. 
In the GEMINI 2 study, the positive result was found in 
4.1% of the patients. If the patient does not have a history of 
abnormal reaction to vedolizumab therapy, pretreatment 
with antihistamine, corticosteroid, or acetaminophen is not 
needed. Combination therapy with an immunomodulator is 
related with suppression of antibody production on medica-
tion.231,232 Therefore, combination therapy with vedolizumab 
and immunomodulator is recommended. Considering the 
effect and safety during the 1-year treatment, continuous use 
for remission maintenance is recommended if the patient 
responded to the remission induction therapy.
SURGICAL THERAPY
45. The absolute indications of surgery for UC are uncon-
trolled bleeding, perforation, and malignancy. Other 
indications can be severe UC that does not respond to 
medical treatment, toxic megacolon, uncontrolled symp-
toms, and cases where continuous medication is impos-
sible because of adverse effects (quality of evidence, 
moderate; classification of recommendation, strong).
• Level of agreement: strongly agree 65.2%, agree 34.8%, 
uncertain 0%, disagree 0%, strongly disagree 0%
46. The standard surgical methods for UC are total proc-
tocolectomy and ileal pouch-anal anastomosis (IPAA). 
IPAA can be made by using stapled anastomosis, and 
mucosectomy is not always necessary (quality of evi-
dence, moderate; classification of recommendation, 
weak).
• Level of agreement: strongly agree 6.8%, agree 79.6%, 
uncertain 13.6%, disagree 0%, strongly disagree 0%
When making a decision for UC surgery, a compromise 
must be made among gastroenterologists, colorectal sur-
geon, and the patient. Common surgical indications in UC 
are complications such as severe UC unresponsive to treat-
ment, occurrence of dysplasia or malignancy, bleeding, per-
foration, and toxic megacolon.
Restorative proctocolectomy with IPAA was first intro-
duced in 1978 and is still used as the standard surgery.233 
Stapled anastomosis is preferred for preservation of anal 
function during the IPAA. The recommended residual rectal 
length is within 2 cm. This will lower the rate of future oc-
currence of inflammation or rectal mucosal malignancy. 
Mucosectomy and hand-sewn anastomosis show anal dys-
function when compared with stapled anastomosis.234 It is 
not always indicated because of insufficient evidence that 
it prevents the occurrence of dysplasia or colon cancer.235 
Temporary loop ileostomy can lower the rates of morbidity 
and mortality rate by lowering the risk of anastomotic leak-
age and pelvic sepsis.236
Laparoscopic reconstructive proctocolectomy has cos-
metic advantages and is associated with lesser pain, faster 
recovery, and shorter length of hospital stay. Therefore, it is a 
useful operation method for elective surgery for UC. Opera-
tion hours are longer than those in open surgery. However, 
the complication rate is similar or lower.237 In long-term 
follow-up, laparoscopic surgery lowers the possibility of in-
traperitoneal adhesion and abdominal hernia, and improves 
the possibility of pregnancy.238
As emergency operation due to bleeding, toxic megaco-
lon, perforation, or fulminant UC, total colectomy and end 
ileostomy are preferred. These surgical methods preserve 
the rectum and only remove the colon. When the patient 
enters a stable state, 1- or 2-staged reconstruction surgery 
is performed. This operation method can be considered in 
patients with acute severe UC who have used ≥20 mg/day 
prednisolone continuously for over 6 weeks. Subtotal col-
ectomy, rectosigmoid fistula, or Hartmann’s procedure can 
be the alternative choices.239 Laparoscopic operation has 
many advantages in emergent cases. However, it must be 
performed by surgeons who have sufficient experience with 
laparoscopic procedures and UC treatments.
CONCLUSIONS
UC is a chronic IBD characterized by bloody diarrhea, ur-
gency, and abdominal pain. The incidence and prevalence 
of UC are constantly increasing during the past decades in 
Korea, and many patients have been diagnosed with the dis-
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ease. However, the exact pathophysiology of the disease and 
the treatment methods for cure remain unknown. Although 
various medical and surgical therapies have been advanced 
for the management of UC, many challenging issues lead 
to differences in practice between clinicians. We are hoping 
that this Korean guidelines will prevent unnecessary or inap-
propriate, or delayed treatments and lessen the confusion 
among physicians and researchers. South Korea has insuf-
ficient data on UC, but many studies are currently progress-
ing. We hope that more Korean data will be reflected in the 
next revised version of the Korean guidelines for the man-
agement of UC.
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